HTCC as a highly effective polymeric inhibitor of SARS-CoV-2 and MERS-CoV
Milewska, A.; Chi, Y.; Szczepanski, A.; Barreto-Duran, E.; Liu, K.; Liu, D.; Guo, X.; Ge, Y.; Li, J.; Cui, L.; Ochman, M.; Urlik, M.; Rodziewicz-Motowidlo, S.; Zhu, F.; Szczubialka, K.; Nowakowska, M.; Pyrc, K.
Show abstract
The beginning of 2020 brought us information about the novel coronavirus emerging in China. Rapid research resulted in the characterization of the pathogen, which appeared to be a member of the SARS-like cluster, commonly seen in bats. Despite the global and local efforts, the virus escaped the healthcare measures and rapidly spread in China and later globally, officially causing a pandemic and global crisis in March 2020. At present, different scenarios are being written to contain the virus, but the development of novel anticoronavirals for all highly pathogenic coronaviruses remains the major challenge. Here, we describe the antiviral activity of previously developed by us HTCC compound (N-(2-hydroxypropyl)-3-trimethylammonium chitosan chloride), which may be used as potential inhibitor of currently circulating highly pathogenic coronaviruses - SARS-CoV-2 and MERS-CoV.
Matching journals
The top 12 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Antiviral activity of lambda-carrageenan against influenza viruses in mice and severe acute respiratory syndrome coronavirus 2 in vitro 95%
- Nebulized 2-deoxylated glucose analogues inhibit respiratory viral infection in advanced in vitro airway models 94%
- Gamma-irradiated SARS-CoV-2 vaccine candidate, OZG-38.61.3, confers protection from SARS-CoV-2 challenge in human ACEII-transgenic mice 93%
Similar papers in this journal
- Brilacidin, a COVID-19 Drug Candidate, demonstrates broad-spectrum antiviral activity against human coronaviruses OC43, 229E and NL63 through targeting both the virus and the host cell 94%
- In Vitro Activity of Itraconazole Against SARS-CoV-2 92%
- Development and optimisation of a high-throughput screening assay for in vitro anti-SARS-CoV-2 activity: evaluation of 5676 phase 1 passed structures 92%
Similar papers in this journal
- SARS-CoV-2 fears green: the chlorophyll catabolite Pheophorbide a is a potent antiviral 94%
- Methylene Blue Is a Nonspecific Protein-Protein Interaction Inhibitor with Potential for Repurposing as an Antiviral for COVID-19 93%
- Atazanavir is a competitive inhibitor of SARS-CoV-2 Mpro, impairing variants replication in vitro and in vivo 93%
Similar papers in this journal
- Discovery of anti-SARS-CoV-2 S2 protein antibody CV804 with broad-spectrum reactivity with various beta coronaviruses and analysis of its pharmacological properties in vitro and in vivo 94%
- Evaluation of silver nanoparticles for the prevention of SARS-CoV-2 infection in health workers: in vitro and in vivo 92%
- Fluorinated oil-surfactant mixtures with the density of water: artificial cells for synthetic biology 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.